コーパス検索結果 (1語後でソート)
通し番号をクリックするとPubMedの該当ページを表示します
1 to prevent new episodes of thrombosis ("pure secondary prevention").
2 older adults with already impaired function (secondary prevention).
3 on of and nonadherence to statin therapy for secondary prevention.
4 ning is common, providing an opportunity for secondary prevention.
5 potential implications in CRC screening and secondary prevention.
6 placebo-controlled trial of pioglitazone for secondary prevention.
7 ure combinations could facilitate its use in secondary prevention.
8 e (ie, cryptogenic), potentially undermining secondary prevention.
9 without comorbidities on statin therapy for secondary prevention.
10 ocardial infarction (MI) is a cornerstone of secondary prevention.
11 r PAD, both for symptomatic patients and for secondary prevention.
12 isk of CVD and receiving effective drugs for secondary prevention.
13 or type of endpoint and in both primary and secondary prevention.
14 festyle programs with regular hospital-based secondary prevention.
15 ent of HE, while seven looked at its primary/secondary prevention.
16 reduction was comparable to that achieved in secondary prevention.
17 nt the implementation of optimal primary and secondary prevention.
18 from 12 trials of aspirin versus control in secondary prevention.
19 n (14%), chronic angina treatment (13%), and secondary prevention (11%) made the largest medical cont
20 III trial, 477 received a defibrillator for secondary prevention; 248 patients were randomly assigne
21 o determine the association between baseline secondary prevention achievement and cardiovascular deat
24 stroke prevention in atrial fibrillation and secondary prevention after acute coronary syndromes, pro
26 re 4.5% per year overall, 14.0% per year for secondary prevention after cardiac arrest, and 3.1% per
29 as a risk factor requiring intervention for secondary prevention after percutaneous coronary revascu
31 ndomised trials of aspirin versus control in secondary prevention after TIA or ischaemic stroke, we s
33 will be difficult to deploy, strategies for secondary prevention aimed at later stages of disease ar
34 ucing the rate of unplanned conceptions, and secondary prevention aimed at modification of health beh
35 viously symptomatic patients who had LCSD as secondary prevention, all had an attenuation in cardiac
36 sis in Myocardial Infarction) Risk Score for Secondary Prevention, all patients with DM demonstrated
37 have assessed the role of supplementation in secondary prevention among patients with diabetes mellit
38 rence by 33% compared with usual care in CVD secondary prevention and has been recommended as a "best
39 ally when antithrombotic therapy is used for secondary prevention and is withdrawn perioperatively.
40 ases because of its well-established role in secondary prevention and its widespread availability and
41 In the article by Smith et al, "AHA/ACCF Secondary Prevention and Risk Reduction Therapy for Pati
42 ibitors or angiotensin receptor blockers for secondary prevention and treatment of angina doubled, fr
43 assessed in cardiovascular disease patients (secondary prevention) and for two blood pressure ranges
44 ith pre-existing occlusive vascular disease (secondary prevention) and in 500 patients (ie, 5% absolu
47 ional insurance to cover primary prevention, secondary prevention, and tertiary treatment for cardiov
48 finding emphasises the importance of urgent secondary prevention, and the role of stenting for verte
49 rojects will inform the development of novel secondary prevention approaches and underpin the careers
50 tegies to address gaps in lipid lowering for secondary prevention are essential to maximize reduction
52 scents, and children and maintain and target secondary prevention at the population older than 60 yea
53 ditional differentiation between primary and secondary prevention based simply on clinical history.
54 te ischemic stroke are in need of hyperacute secondary prevention because the risk of recurrence is h
56 of death (Ptrend<0.001 for both primary and secondary prevention) but no significant decline in appr
60 ist to improve the quality of cardiovascular secondary prevention care among patients with diabetes m
61 h primary prevention (JUPITER and ASCOT) and secondary prevention (CARE and PROVE IT-TIMI 22) with st
62 with no prior cardiovascular event, and the secondary prevention cohort comprised individuals >/=30
63 of UGIB was lower in the primary than in the secondary prevention cohort, numbers needed to harm per
65 strategies for studying diseases subject to secondary prevention, comparing the following: 1) CRC ca
66 Medical directors of cardiac rehabilitation/secondary prevention (CR/SP) programs are responsible fo
68 d Prevention, efforts to improve primary and secondary prevention effectiveness center on policy deve
75 VD, including tobacco use, hypertension, and secondary prevention for CVD, will lead to the biggest g
77 e failure of homocysteine-lowering trials in secondary prevention from thrombotic vascular events.
78 imary end point event rate was higher in the secondary prevention group compared with the primary pre
80 ng copayments for post-myocardial infarction secondary prevention has beneficial effects, but the imp
82 Although drug-eluting stents and intensive secondary prevention have contributed to improved outcom
85 ovascular events and benefit from aggressive secondary prevention; however, changes in the use of car
86 he primary (HR, 0.98; 95% CI, 0.74-1.30) and secondary prevention (HR, 0.82; 95% CI, 0.72-0.95) cohor
87 gh-risk (HR: 0.89; 95% CI: 0.83 to 0.95) and secondary prevention (HR: 0.89; 95% CI: 0.83 to 0.96) po
88 gh-risk (HR: 1.11; 95% CI: 0.83 to 1.49) and secondary prevention (HR: 1.08; 95% CI: 0.79 to 1.47) su
89 Registry ICD Registry undergoing first-time secondary prevention ICD implantation between 2006 and 2
94 iomyopathy index cases, 44 patients received secondary prevention implantable cardioverter-defibrilla
97 in receptor blocker (ARB) should be used for secondary prevention in all or in only high-risk patient
98 ls comparing anticoagulants with aspirin for secondary prevention in arterial thrombosis and aspirin
99 rtality of older patients receiving ICDs for secondary prevention in contemporary clinical practice.
100 w-dose aspirin may have a continuing role in secondary prevention in HF and underline the need for mo
101 ce the importance of acute clinical care and secondary prevention in improving long-term prognosis of
102 efforts to target early Abeta deposition for secondary prevention in individuals with autosomal domin
103 tations for primary prevention compared with secondary prevention in inherited cardiac diseases.
104 besity paradox have led to uncertainty about secondary prevention in obese patients with stroke.
106 hough statin medications are recommended for secondary prevention in peripheral arterial disease, the
107 -modifying agents in mild AD patients or via secondary prevention in presymptomatic subjects bearing
108 igh risk inherited arrhythmic conditions and secondary prevention in survivors of sudden cardiac arre
109 527 users of low-dose aspirin for primary or secondary prevention in the Swedish prescription registe
110 y treatments are worthy of consideration for secondary prevention in these patients if ongoing trials
112 lomavirus testing is clinically valuable for secondary prevention in triaging low-grade cytology and
114 eatment should include guideline-recommended secondary prevention, including antiplatelet and antiath
115 lthough eliminating patient cost sharing for secondary prevention increases adherence and reduces rat
116 -multimineral treatment, used for primary or secondary prevention, increases the risk of mortality in
117 acceptability are low for medicines used in secondary prevention; increasing use is positively relat
118 sease (2 points); renal dialysis (3 points); secondary prevention indication (1 point); and ICD type:
120 dence interval: 1.87 to 13.14; p < 0.01) and secondary prevention indication (hazard ratio: 6.85; 95%
126 This therapy, which is sometimes labeled as secondary prevention, is effective in preventing recurre
129 n Follow-up Care, Surveillance Protocol, and Secondary Prevention Measures for Survivors of Colorecta
132 This study assessed practice variations in secondary prevention medication prescriptions among coro
133 re likely to be discharged on evidence-based secondary prevention medication therapies compared with
136 Whether patients receive optimal dosing of secondary prevention medications at the time of and afte
137 s after an AMI are discharged on appropriate secondary prevention medications, dose increases occur i
140 men) received an S-ICD for primary (n=17) or secondary prevention (n=23 [58%]) at 3 institutions in G
141 with chronic angina (n=33 211) or requiring secondary prevention (n=32 976) in 1999 and 2007 were ex
142 ng signs or symptoms and survival depends on secondary prevention, notably prompt initiation of cardi
144 outlines current strategies for primary and secondary prevention of anthracycline-induced cardiotoxi
145 Despite the strong evidence for CR in the secondary prevention of ASCVD, it remains vastly underut
148 ational studies support statin treatment for secondary prevention of atherosclerotic cardiovascular d
149 ensity statin therapy is recommended for the secondary prevention of atherosclerotic cardiovascular d
150 er high-dose multivitamins are effective for secondary prevention of atherosclerotic disease is unkno
154 A2P-TIMI 50 (Thrombin Receptor Antagonist in Secondary Prevention of Atherothrombotic Ischemic Events
155 nts from the Thrombin Receptor Antagonist in Secondary Prevention of Atherothrombotic Ischemic Events
156 s P-TIMI 50 [Thrombin Receptor Antagonist in Secondary Prevention of Atherothrombotic Ischemic Events
158 eview highlights advances in the primary and secondary prevention of cardiovascular disease (CVD) in
159 py, which is the cornerstone for primary and secondary prevention of cardiovascular disease, fails in
160 ors), commonly prescribed in the primary and secondary prevention of cardiovascular disease, promote
163 the use of pharmacological treatment for the secondary prevention of cardiovascular diseases (CVD), s
164 miological and ET studies in the primary and secondary prevention of cardiovascular diseases, particu
165 s of low-dose acetylsalicylic acid (ASA) for secondary prevention of cardiovascular events in a UK pr
166 ing opportunities to improve the primary and secondary prevention of cardiovascular events in Ontario
168 e shown that statins help in the primary and secondary prevention of cardiovascular events, not only
173 e and Pubmed articles related to primary and secondary prevention of CRC and subsequently, a meta-ana
177 re seems as effective as medical therapy for secondary prevention of cryptogenic ischemic stroke.
179 ials of supplementation of EPA+DHA or ALA in secondary prevention of CVD showed no clear benefit.
180 ntinued investment is crucial in primary and secondary prevention of deaths due to congenital abnorma
181 icoagulant rivaroxaban for the treatment and secondary prevention of deep-vein thrombosis and pulmona
182 an expected at all ages, and ineffective for secondary prevention of diarrhea in children <12 mo of a
183 esting direct-acting oral anticoagulants for secondary prevention of embolic strokes of undetermined
184 ure to that of medical therapy alone for the secondary prevention of embolism in patients with patent
186 ansfusion is the optimal current therapy for secondary prevention of infarcts for children with SCA a
189 ng the challenges of survivorship, including secondary prevention of long-term morbidity and mortalit
190 rtery disease receive aspirin for primary or secondary prevention of myocardial infarction, stroke, a
191 Further evidence that BPs dispensed for secondary prevention of osteoporotic fractures are not a
194 this intervention could also be effective in secondary prevention of prolapse and the need for future
195 ar in childhood and adolescence, primary and secondary prevention of psychiatric disorders offers the
197 ore effective than medical treatment for the secondary prevention of recurrent cerebrovascular events
198 fectiveness of AIT and its potential role in secondary prevention of respiratory allergy progression.
201 All English-speaking participants in the Secondary Prevention of Small Subcortical Strokes (SPS3)
202 eds (CMBs) in lacunar stroke patients in the Secondary Prevention of Small Subcortical Strokes (SPS3)
203 ecent meta-analyses and randomized trials on secondary prevention of squamous cell carcinoma observed
204 stenosis, surgical intervention as a part of secondary prevention of stroke has become widespread.
205 e to assist in the diagnosis, treatment, and secondary prevention of stroke in patients in whom an in
208 table cardioverter-defibrillators (ICDs) for secondary prevention of sudden cardiac death were conduc
214 antiplatelet drugs to aspirin for long-term secondary prevention of thrombotic events in stable pati
215 of this study is to determine the effect of secondary prevention of vascular events on cognitive fun
216 e may therefore be considered for primary or secondary prevention of vascular events with regard to t
217 roxaban is established for the treatment and secondary prevention of venous thromboembolism, but whet
221 ithin 2 years of randomization or an ICD for secondary prevention of VT/VF within 6 months of randomi
222 us and cardiovascular disease achieved all 5 secondary prevention parameters at baseline, although 71
225 l-group trial that enrolled 1902 primary and secondary prevention patients (mean [SD] age, 65 [11] ye
227 erminants of residual risk in statin-treated secondary prevention patients included lipid-related and
235 n window setting in ICDs in both primary and secondary prevention populations and demonstrates a redu
236 trum of dyslipidemia, event rates similar to secondary prevention populations were observed for patie
238 treatment, and are unlikely to benefit from secondary prevention recommendations to limit disease pr
240 an 3.0 years of follow-up, a higher baseline secondary prevention score was associated with improved
241 herapy, vorapaxar administered for long-term secondary prevention significantly reduced ARC definite
242 er results are different during the phase of secondary prevention starting after hospital discharge,
243 Concomitantly, risk factor management and secondary prevention strategies among vascular patients
244 uture studies targeting greater adherence to secondary prevention strategies and novel therapies are
245 es could be leveraged to promote primary and secondary prevention strategies for these infections to
248 tus for whom closer follow-up and aggressive secondary prevention strategies should be considered.
250 Such information will assist in identifying secondary prevention strategies to arrest the atopic mar
253 trophy may be a feasible outcome measure for secondary prevention studies in asymptomatic amyloidosis
256 grade patients were more often implanted for secondary prevention, suffered more often from atrial fi
257 Despite clear evidence of benefit for CAD secondary prevention, the level of risk factor control i
258 ed in addition to statins and other standard secondary prevention therapies appeared effective for th
259 ischemia-producing lesions and intensifying secondary prevention therapies as on the prevention of r
261 w-up data exist on the impact of appropriate secondary prevention therapies on cognitive function in
263 s (THs) more consistently use evidence-based secondary prevention therapies than non-THs (NTHs).
265 phylactic HPV vaccination; and prospects for secondary prevention through screening for oral HPV infe
266 sterol treatment and control for men, stroke secondary prevention through treatment and control of va
267 supplements to dietary intake and evaluated secondary prevention, thus limiting inference for dietar
273 OMega-3 fatty acids (SU.FOL.OM3) trial was a secondary prevention trial (2003-2009; n = 2501) in whic
275 ch 1-mmol/L lower LDL-C level; P = .008) and secondary prevention trials (4.6% lower event rate [95%
276 VTE as a prospective end point in long-term secondary prevention trials evaluating the risks and ben
277 ome a prerequisite for enrollment in several secondary prevention trials for AD, yet the precise effe
279 Several large-scale Alzheimer disease (AD) secondary prevention trials have begun to target individ
283 actors are important to consider in upcoming secondary prevention trials targeting CN individuals at
284 al (CN) individuals is critical for upcoming secondary prevention trials using cognitive outcomes.
292 sis In Myocardial Infarction) Risk Score for Secondary Prevention (TRS 2 degrees P) is a simple 9-poi
294 adults with prior cardiovascular disease for secondary prevention was projected to be cost saving in
296 r-defibrillator implantation for primary and secondary preventions were retrospectively analyzed.
297 s to prevent the onset of IgE sensitization; secondary prevention, which seeks to interrupt the devel
298 y, and the use of endovascular therapies for secondary prevention, which, so far, have not shown any
300 Treating all hypertension for primary and secondary prevention would prevent about 800,000 cardiov
WebLSDに未収録の専門用語(用法)は "新規対訳" から投稿できます。